Cantor Fitzgerald Raises Target Price for Amgen Stock
Cantor Fitzgerald has increased its target price for Amgen (NASDAQ:AMGN) stock from $350.00 to $400.00 in a recent research report.
This change suggests a potential downside of 4.62% from the company's current price, which was trading at $419.38 on Tuesday.
The firm currently has a 'neutral' rating on Amgen's stock and joins other brokerages that have recently issued reports on the medical research company.